Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
| Brand name | METFORMIN HYDROCHLORIDE |
| Generic name | METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, MD |
| NDC | 68180-336-07 |
| Full product label | Metformin Hydrochloride Extended-release Tablets USP, 500 mg, 60 count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD Manufactured by: Lupin Limited Goa INDIA (NDC 68180-336-07) |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed throughout the United States. |
| Quantity | 6,540 bottles |
| Recall initiated | 2020-06-11 |
| Report date | 2020-07-01 |
| Recall completed | 2021-12-23 |
| Recall number | D-1334-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗